Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Flatiron Health Joins Hands with National Cancer Center to Start Up Japan Biz
January 27, 2022
- Seikagaku Launches New Outpost in Canada
January 27, 2022
- Nippon Shinyaku Sets Up New Sales Firm in Tianjin to Expand Chinese Business
January 27, 2022
- Astellas to Revamp Japan Marketing Organization, Scrap Sales Offices as Biz Environment Evolves
January 26, 2022
- Nippon Shinyaku Snags US Commercial Rights to Capricor’s DMD Cell Therapy
January 26, 2022
- MSD Japan Set to Supply 1.6 Million Courses of Lagevrio by September: President
January 26, 2022
- Opdivo Combo Approved in Taiwan for 1st Line Non-Squamous NSCLC
January 26, 2022
- Abraxane Supply Secured until around July: Taiho
January 26, 2022
- Astellas Aims to Propel Digital Transformation to Become Value-Driven Innovator
January 25, 2022
- Aculys Pharma Gets APAC Rights to Neurelis’ Epilepsy Nasal Spray
January 25, 2022
- Novartis Downsizing Tokyo Head Office to Cut Costs and Support Diverse Work Styles
January 24, 2022
- Daiichi Sankyo to End Vaccine Collaboration with Kitasato Pharma
January 24, 2022
- JCR’s MPS IIIA Drug Gets Orphan Tag in Europe
January 24, 2022
- Shipment Control Lifted for Pfizer's Methotrexate Injection After One Year
January 21, 2022
- Shionogi Submits PI Data for Oral COVID-19 Drug in Japan
January 21, 2022
- FunPep, EPS Group in Talks to Codevelop Peptide Drugs in China
January 21, 2022
- BMS’ Second CAR-T Therapy Abecma Approved in Japan
January 21, 2022
- Fuji Pharma Slapped with Biz Improvement Order over GMP Violations
January 20, 2022
- Daiichi Sankyo to Offload 8 US Assets to Cosette
January 20, 2022
- Katarzyna Maria Witkos Takes Helm at Alnylam Japan
January 20, 2022
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…